Approved for Prevention of RSV-associated lower respiratory tract disease in adults 60 years of age and older. mResvia is an mRNA-based vaccine that encodes the prefusion-stabilized F glycoprotein of respiratory syncytial virus. After injection, cells produce the RSV F protein, stimulating an immune response… Side effects, costs, interactions, manufacturer, and generic alternatives sourced from…
Loading full data from Know Your Drugs Institute…